Tripep receives a first patent in the EU on the use of ribavirin as a vaccine adjuvant

Tripep has today been granted a first patent in the EU for the use of ribavirin as an immune stimulating adjuvant for vaccines containing proteins or DNA. The patent protects all immunogenic compositions that comprise ribavirin and a viral, bacterial, mould, or yeast antigen or a nucleic acid encoding the same. Specific claims protect immunogenic compositions that comprise ribavirin and hepatitis virus antigens, which will pave the way for the introduction of new drugs and treatment protocols for hepatitis C virus and hepatitis B virus infections. This is the first EU patent that Tripep has been granted for Tripep’s Ribacine technology. Patents that protect Tripep’s Ribacine technology have already been granted in the United States.

”We are very happy about our first patent on the Ribacine technology in the EU. This strengthens our efforts in developing effective vaccines adjuvants and new approaches for the treatment and prevention of hepatitis” says Tripep’s CEO Mr. Jan Nilsson.



For more information, please contact:

Jan Nilsson, CEO, Tripep AB
Tel: +46 8 449 84 80, mobile phone: +46 70 466 31 63, E-mail: jan.nilsson@tripep.se

Anders Vahlne, Head of Research, Tripep AB
Tel: +46 8 5858 1313, mobile phone: +46 709 28 05 28, E-mail: anders.vahlne@ki.se